LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 3 von insgesamt 3

Suchoptionen

  1. Artikel ; Online: Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study.

    Wang-Gillam, Andrea / Lim, Kian-Huat / McWilliams, Robert / Suresh, Rama / Lockhart, Albert C / Brown, Amberly / Breden, Marcus / Belle, Jad I / Herndon, John / Bogner, Savannah J / Pedersen, Katrina / Tan, Benjamin / Boice, Nicholas / Acharya, Abhi / Abdiannia, Mina / Gao, Feng / Yoon, Harry H / Zhu, Mojun / Trikalinos, Nikolaos A /
    Ratner, Lee / Aranha, Olivia / Hawkins, William G / Herzog, Brett H / DeNardo, David G

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2023  Band 29, Heft 22, Seite(n) 4698

    Sprache Englisch
    Erscheinungsdatum 2023-11-14
    Erscheinungsland United States
    Dokumenttyp Published Erratum
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-23-2993
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 4223: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies.

    Lim, Kian-Huat / Opyrchal, Mateusz / Acharya, Abhi / Boice, Nick / Wu, Ningying / Gao, Feng / Webster, Jace / Lockhart, Albert C / Waqar, Saiama N / Govindan, Ramaswamy / Morgensztern, Daniel / Picus, Joel / Tan, Benjamin R / Baggstrom, Maria Q / Maher, Christopher A / Wang-Gillam, Andrea

    European journal of cancer (Oxford, England : 1990)

    2021  Band 154, Seite(n) 102–110

    Abstract: Aim: Aurora kinase A (AURKA) is a pleiotropic serine/threonine kinase that orchestrates mitotic progression. Paclitaxel stabilises microtubules and disrupts mitotic spindle assembly. The combination of AURKA inhibitor (alisertib) plus paclitaxel may be ... ...

    Abstract Aim: Aurora kinase A (AURKA) is a pleiotropic serine/threonine kinase that orchestrates mitotic progression. Paclitaxel stabilises microtubules and disrupts mitotic spindle assembly. The combination of AURKA inhibitor (alisertib) plus paclitaxel may be synergistic in rapidly proliferative cancers. We evaluated the safety and maximum tolerated dose (MTD) of alisertib in combination with nab-paclitaxel and its preliminary efficacy in patients with refractory high-grade neuroendocrine tumours (NETs).
    Method: This is a two-part, Phase 1 study. In Part A (dose escalation), a standard 3 + 3 design was used to determine MTD. In Part B (dose expansion), patients with predominantly refractory high-grade NETs were enrolled.
    Results: In total, 31 patients were enrolled and treated (16 in Part A and 15 in Part B). The MTD of alisertib was 40 mg BID on D1-3 per week and nab-paclitaxel 100mg/m
    Conclusions: The combination of alisertib and nab-paclitaxel has manageable side-effect profile and showed promising preliminary efficacy in high-grade NETs, warranting further testing.
    Trial registration: ClinicalTrials.gov identifier: NCT01677559.
    Mesh-Begriff(e) Adult ; Aged ; Albumins/administration & dosage ; Albumins/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Azepines/administration & dosage ; Azepines/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Neuroendocrine Tumors/drug therapy ; Neuroendocrine Tumors/mortality ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects
    Chemische Substanzen 130-nm albumin-bound paclitaxel ; Albumins ; Azepines ; MLN 8237 ; Pyrimidines ; Paclitaxel (P88XT4IS4D)
    Sprache Englisch
    Erscheinungsdatum 2021-07-10
    Erscheinungsland England
    Dokumenttyp Clinical Trial, Phase I ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 82061-1
    ISSN 1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
    ISSN (online) 1879-0852
    ISSN 0277-5379 ; 0959-8049 ; 0964-1947
    DOI 10.1016/j.ejca.2021.06.012
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 456: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 583: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.

    Wang-Gillam, Andrea / Lim, Kian-Huat / McWilliams, Robert / Suresh, Rama / Lockhart, Albert C / Brown, Amberly / Breden, Marcus / Belle, Jad I / Herndon, John / Bogner, Savannah J / Pedersen, Katrina / Tan, Benjamin / Boice, Nicholas / Acharya, Abhi / Abdiannia, Mina / Gao, Feng / Yoon, Harry H / Zhu, Mojun / Trikalinos, Nikolaos A /
    Ratner, Lee / Aranha, Olivia / Hawkins, William G / Herzog, Brett H / DeNardo, David G

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2022  Band 28, Heft 24, Seite(n) 5254–5262

    Abstract: Purpose: Targeting focal adhesion kinase (FAK) renders checkpoint immunotherapy effective in pancreatic ductal adenocarcinoma (PDAC) mouse model. Defactinib is a highly potent oral FAK inhibitor that has a tolerable safety profile.: Patients and ... ...

    Abstract Purpose: Targeting focal adhesion kinase (FAK) renders checkpoint immunotherapy effective in pancreatic ductal adenocarcinoma (PDAC) mouse model. Defactinib is a highly potent oral FAK inhibitor that has a tolerable safety profile.
    Patients and methods: We conducted a multicenter, open-label, phase I study with dose escalation and expansion phases. In dose escalation, patients with refractory solid tumors were treated at five escalating dose levels of defactinib and gemcitabine to identify a recommended phase II dose (RP2D). In expansion phase, patients with metastatic PDAC who progressed on frontline treatment (refractory cohort) or had stable disease (SD) after at least 4 months of standard gemcitabine/nab-paclitaxel (maintenance cohort) were treated at RP2D. Pre- and posttreatment tumor biopsies were performed to evaluate tumor immunity.
    Results: The triple drug combination was well-tolerated, with no dose-limiting toxicities. Among 20 treated patients with refractory PDAC, the disease control rate (DCR) was 80%, with one partial response (PR) and 15 SDs, and the median progression-free survival (PFS) and overall survival (OS) were 3.6 and 7.8 months, respectively. Among 10 evaluable patients in the maintenance cohort, DCR was 70% with one PR and six SDs. Three patients with SD came off study due to treatment- or disease-related complications. The median PFS and OS on study treatment were 5.0 and 8.3 months, respectively.
    Conclusions: The combination of defactinib, pembrolizumab, and gemcitabine was well-tolerated and safe, had promising preliminary efficacy, and showed biomarker activity in infiltrative T lymphocytes. Efficacy of this strategy may require incorporation of more potent chemotherapy in future studies.
    Mesh-Begriff(e) Animals ; Mice ; Gemcitabine ; Deoxycytidine ; Albumins ; Paclitaxel ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Pancreatic Neoplasms/pathology ; Adenocarcinoma/pathology ; Pancreatic Neoplasms
    Chemische Substanzen Gemcitabine ; defactinib (53O87HA2QU) ; Deoxycytidine (0W860991D6) ; pembrolizumab (DPT0O3T46P) ; Albumins ; Paclitaxel (P88XT4IS4D)
    Sprache Englisch
    Erscheinungsdatum 2022-10-14
    Erscheinungsland United States
    Dokumenttyp Clinical Trial, Phase I ; Multicenter Study ; Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-22-0308
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 4223: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang